Ninety One SA PTY Ltd Boosts Holdings in Johnson & Johnson $JNJ

Key Points

• Ninety One SA PTY Ltd increased its holdings in Johnson & Johnson by 46.2% during the second quarter, now owning nearly 100,000 shares valued at approximately $15 million.
• Several institutional investors have also raised their stakes in Johnson & Johnson, with institutional ownership now at 69.55% of the company's stock.
• JPMorgan and other firms have updated their target prices for Johnson & Johnson, with a consensus rating now at "Moderate Buy" and an average price target of $181.40.

Ninety One SA PTY Ltd raised its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 46.2% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 99,691 shares of the company's stock after purchasing an additional 31,524 shares during the quarter. Johnson & Johnson accounts for about 2.5% of Ninety One SA PTY Ltd's investment portfolio, making the stock its 12th biggest holding. Ninety One SA PTY Ltd's holdings in Johnson & Johnson were worth $15,198,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Highline Wealth Partners LLC lifted its holdings in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC bought a new position in Johnson & Johnson during the 1st quarter valued at about $47,000. 1248 Management LLC purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at about $48,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson in the first quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of Johnson & Johnson during the first quarter valued at approximately $52,000. Institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on JNJ. JPMorgan Chase & Co. lifted their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 16th. Morgan Stanley upped their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Guggenheim upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price target for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Finally, Barclays increased their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average price target of $181.40.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $185.98 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a fifty day moving average price of $175.78 and a 200-day moving average price of $162.66. The stock has a market cap of $447.91 billion, a PE ratio of 19.89, a price-to-earnings-growth ratio of 2.37 and a beta of 0.40. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $186.59.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the prior year, the company posted $2.82 earnings per share. The business's quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.